Related Experiment Video

Updated: Oct 10, 2025

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

15.9K

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists

Charalampos Fragkoulis1, Ioannis Glykas1, Athanasios Dellis2

  • 1Department of Urology, General Hospital of Athens 'G. Gennimatas', Mesogeion Avenue 154, Athens, P.C, 115 27, Greece.

Arab Journal of Urology
|December 9, 2021
PubMed

Insights

Androgen-deprivation therapy (ADT) for metastatic prostate cancer now includes relugolix, an oral gonadotrophin-releasing hormone (GnRH) antagonist. This novel treatment offers efficacy comparable to existing methods while avoiding injection site reactions associated with other GnRH antagonists.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Androgen-deprivation therapy (ADT) is crucial for metastatic prostate cancer.
  • Gonadotrophin-releasing hormone (GnRH) antagonists offer rapid castration with fewer adverse events than agonists.
  • Degarelix is the only currently used GnRH antagonist, with injection site reactions being common.

Purpose of the Study:

  • To review novel data on relugolix as an ADT for prostate cancer.
  • To highlight the advantages of oral administration and reduced adverse events.
  • To present relugolix as a new therapeutic option in prostate cancer management.

Main Methods:

  • Review of clinical data and studies on relugolix.
  • Comparison of relugolix efficacy and safety profile with existing ADT regimens.
  • Analysis of patient-reported outcomes and administration convenience.

Main Results:

  • Relugolix is the first orally administered GnRH antagonist approved by the FDA.
  • Clinical efficacy of relugolix is equivalent to established ADT regimens.
  • Relugolix avoids injection site reactions common with GnRH antagonists like degarelix.

Conclusions:

  • Relugolix offers a patient-friendly oral alternative for ADT in prostate cancer.
  • It provides comparable efficacy to injectable GnRH antagonists and agonists.
  • The avoidance of injection site reactions represents a significant advantage for patient compliance and quality of life.
Keywords:
Relugolixandrogen-deprivation therapynovel drugsprostate cancer

More Related Videos

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

7.8K
Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome04:49

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome

Published on: July 5, 2024

1.3K

Related Concept Videos

Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
1.9K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
791
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
469
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
4.2K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
2.1K
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
1.2K